Once-Weekly Pediatric Growth Hormone Snags FDA Approval
Somatrogon injection given go-ahead after initial FDA rejection last year
Source: medpagetoday.com
Joel Steelman News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Joel Steelman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Joel Steelman Today - Breaking & Trending Today
FDA Approves Pfizer, OPKO's Once Weekly Ngenla for Human Growth Deficiency in Pediatric Patients
Somatrogon-ghla (Ngenla; Pfizer Inc, OPKO Health Inc) is a subcutaneous injection that is administered once weekly via a device allowing for titration based on patients’ needs.
Source: pharmacytimes.com
FDA Approves Pfizer's NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency
New, longer-acting treatment offers option to reduce the frequency of injections for children with growth hormone deficiency from daily to once-weekly
Source: marketscreener.com
Pfizer Growth Hormone Drug Measures Up at FDA With O.K. for Weekly Dosing
Ngenla, a hormone drug from partners Pfizer and Opko Health, is now FDA approved for treating children with growth hormone deficiency. The once-weekly injectable biologic will compete against an Ascendis Pharma product that won its FDA approval in 2021.
Source: medcitynews.com